查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853475

次要大麻素市場按產品類型、用途、形態、分銷管道、最終用途產業和萃取方法分類－2025-2032年全球預測

Minor Cannabinoids Market by Product Type, Application, Form, Distribution Channel, End Use Industry, Extraction Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，次要大麻素市場將成長至 358.6 億美元，複合年成長率為 8.41%。

主要市場統計數據
基準年 2024 187.9億美元
預計年份：2025年 203.9億美元
預測年份：2032年 358.6億美元
複合年成長率 (%) 8.41%

次要大麻素已從主流大麻素的陰影中脫穎而出，成為科學研究和商業性實驗中一個獨特的領域。這些化合物在大麻植物中的含量較低，因其獨特的藥理作用、感官特性和產品創新潛力而備受關注。隨著研究的深入以及萃取和製劑技術的進步，開發人員、臨床醫生和消費品牌紛紛湧向這些領域，尋求利用次要大麻素的微妙作用。

分析化學和標靶萃取技術的最新進展降低了分離大麻酚和大麻色烯等化合物的技術門檻，而臨床上重新燃起的興趣也促使人們對治療機制進行更深入的研究。同時，消費者對主流大麻素替代品的好奇心，正在催生定位於健康、治療和休閒領域的新產品。隨著智慧財產權、供應鏈韌性和監管政策的清晰度成為關鍵的競爭因素，投資者和策略買家正密切關注這些領域。

因此，各公司正優先考慮將科學檢驗、合規的商業化管道和差異化品牌結合的跨職能策略。有效進入市場需要研發、監管、生產和開發等各職能部門的協同努力，該領域正從手工實驗轉向結構化的產品開發和機構投資。

科學進步、監管調整和不斷變化的消費者期望如何匯聚，從而改變各行業的商業化軌跡和策略重點？

在科學進步、監管變革和消費者需求三者共同推動下，大麻產業正經歷變革性的轉變。在科學方面，分析方法和精密萃取技術的進步使得人們能夠鑑定和分離出比以往更廣泛的微量大麻素，從而揭示出不同的受體相互作用和治療假設。因此，研究計畫正從合法的大麻素擴展到那些具有更微妙或互補生物效應的分子。

監管環境也在不斷變化，各地都在調整監管框架，以適應新的大麻素，調整標籤和檢測要求，並在公共衛生問題和商業性機會之間取得平衡。這些監管調整迫使企業加大合規基礎建設投入，並設計能夠經受更嚴格審查的產品。同時，消費者的行為也不斷演變。注重健康和治療的成熟消費者都要求產品具有針對性配方、來源透明且有科學根據。

為此，現有企業和新參與企業都在不斷完善打入市場策略，強調證據、供應鏈可追溯性和差異化的產品敘事。投資者也越來越關注那些能夠證明其提取流程可重複、分析測試可靠且監管管道清晰的公司。總而言之，這些發展正在加速該領域從探索性應用案例向結構化、可擴展的商業化模式的成熟化進程。

2025年美國關稅調整對小宗大麻素價值鏈的籌資策略、供應鏈韌性與製造夥伴關係的影響

美國關稅政策在2025年前的調整正在重塑跨境供應鏈的經濟格局，迫使企業重新評估其採購和生產佈局。以往依賴國際提領、配方和原料供應的企業，如今正根據影響植物原料、純化分離物和成品原料流通的關稅變化，重新計算到岸成本、前置作業時間和庫存策略。

為因應這些貿易動態，許多企業正在加快近岸外包步伐，優先發展國內資源開採能力，或實現供應商網路多元化，以降低單一來源風險。這些調整不僅出於成本考量，更體現了供應鏈韌性、品管和監管合規方面的戰略意義，尤其是在各國監管機構加強對檢驗結果和原產地證明文件的審查之際。此外，擁有垂直整合營運模式的企業能夠更好地抵禦關稅的影響，因為它們可以內部創造價值並利用內部合規能力。

此外，關稅環境也正在影響夥伴關係模式。契約製造和加工商正在重新評估其服務內容，以幫助面臨貿易成本不斷上漲的跨國客戶。策略性買家、授權人和合資夥伴正在評估聯合生產投資能否在保持產品快速上市的同時抵消關稅風險。因此，企業主管必須將關稅情境納入採購決策和應急計劃，以便在貿易經濟格局變化時保持靈活應對。

一個全面的細分框架揭示了產品類型、應用形式、分銷管道和最終用途提取方法如何決定策略產品和監管選擇。

按產品類型細分，可以明確大麻色烯、大麻酚、大麻酚、Δ-8-四氫大麻酚 (THC) 和四氫大麻酚 (THCV) 的科學和商業性考量，每種成分都具有獨特的藥理學特性，可為配方策略和監管風險評估提供依據。同樣，按應用領域進行細分，可以區分臨床證據要點和消費者定位。醫療應用涵蓋神經病變、疼痛管理、皮膚疾病和睡眠障礙；娛樂應用著重於休閒娛樂和感官增強；而健康應用則著重於膳食補充劑、健身恢復和壓力緩解。這些應用領域直接影響產品宣稱的建置、證據要求和通路適用性。

飲料、偏好、油劑、酊劑和外用製劑在配方、穩定性和劑量方面各有不同，面臨不同的挑戰。在飲料領域，能量飲料、浸泡水和茶等細分產品需要專注於溶解度和感官遮罩。烘焙點心、巧克力和軟糖等偏好產品需要完善的穩定性通訊協定和穩定的活性成分分佈。膏霜、乳霜和乳液等外用製劑則必須考慮皮膚吸收和防腐系統。分銷管道細分區分了不同的消費者管道，從包括成人用藥房、持證零售店和醫療經銷店在內的藥房，到以直接面對消費者和市場策略為中心的電子商務模式，再到醫院和藥房。

依最終用途產業分類，化妝品可細分為護髮、彩妝和護膚；食品飲料可細分為食品飲料、糖果甜點和零嘴零食；營養保健品可細分為機能性食品和膳食補充劑；個人護理和藥品可細分為非處方藥和處方藥管道。最後，按萃取方法分類——亞臨界和超臨界二氧化碳萃取、乙醇萃取、丁烷或丙烷烴萃取以及機械萃取——決定了成本結構、雜質譜和可擴展性。這些細分視角構成了一個多維框架，用於指南微量大麻素生態系統中的產品開發、監管策略和商業性優先排序。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和監管差異，決定了商業化和合規策略的差異性。

美洲、歐洲、中東和非洲以及亞太地區的區域促進因素正在塑造各自不同的研發、監管和商業化路徑，分別代表不同的投資者情緒、消費者偏好和政策環境。在美洲，成熟市場與快速發展的州級法規相結合，推動著治療和成人用藥領域的創新，而商業化相關人員則專注於最佳化檢測基礎設施、供應鏈可追溯性和零售管道。

在歐洲、中東和非洲，監管環境的多樣性和較保守的公共衛生框架通常要求提供嚴格的臨床證據和明確的產品定義。面向這些市場的上市公司專注於藥物研發路徑、醫療產品註冊以及與成熟醫療機構的合作。相較之下，亞太地區情況複雜，文化態度、進口法規和對大麻素產品的容忍度各不相同，因此需要精心製定市場策略。許多公司優先考慮與當地經銷商夥伴關係，按照區域成分標準配製產品，並設計教育計畫以建立消費者信任。

綜上所述，這些區域性洞察表明，成功的市場策略應將本地監管資訊與靈活的生產和分銷模式相結合。策略性參與企業應投資於區域合規、必要的本地臨床和安全測試，以及符合當地文化的行銷，以加速產品推廣，同時降低監管和聲譽風險。

決定市場領導地位的主要企業的能力和競爭優勢，包括萃取技術、配方可擴展性、監管參與度和分銷網路。

在次要大麻素市場，企業在研發、萃取、配方、監管和分銷等方面的能力決定了其競爭地位。主要企業憑藉專有的提取技術、檢驗的分析方法以及將分子特徵轉化為穩定、可重複產品的卓越能力脫穎而出。對於尋求臨床檢驗和機制研究以支持可靠產品聲明的企業而言，與學術研究機構和合約研究機構建立合作關係日益普遍。

生產能力仍然是一項戰略差異化因素，能夠擴大二氧化碳或乙醇萃取規模，同時保持嚴格的雜質監測和批次重複性的公司擁有戰術性優勢。同時，擁有彈性配方平台（可滿足飲料、偏好製劑和口服製劑等多種應用需求）的公司更能適應不斷變化的消費者偏好。分銷實力，無論是透過授權、藥房管道還是強大的直銷電商模式，都能幫助參與企業更快地將產品推向市場，並獲取數據以進行迭代產品改進，從而實現差異化競爭。

智慧財產權和監管備案進一步拉開了市場領導者與新興競爭對手之間的差距。將可防禦的製程智慧財產權與積極主動的監管溝通結合的企業，能夠更快地獲得新產品核准並降低商業風險。這些能力共同構成了策略聯盟、併購和授權交易的基礎。

產業領導者可採取的可操作策略重點是將科學差異化與具有韌性的供應鏈相容的商業化以及值得信賴的消費者提案結合。

為了將技術潛力轉化為商業性成果，產業領導者應優先考慮整合科學檢驗、合規生產和消費者教育的整合策略。首先，他們投資於嚴謹的分析和臨床前研究，以確保產品的可重複性並闡明其作用機制。這些數據資產有助於與臨床研究人員和醫療保健相關人員建立夥伴關係，同時也能為可信賴的市場宣傳提供支持，並減少監管方面的阻力。

第二，我們將實現萃取和生產佈局的多元化，以平衡成本效益和供應鏈韌性。近岸外包、雙重採購以及對可擴展的二氧化碳和乙醇平台的投資將有助於降低貿易風險，並確保產品品質的穩定性。第三，我們將採取針對不同管道的商業化策略。我們將根據藥房和醫療管道的要求，設計符合實證要求的配方和標籤；同時，我們將針對直接面對消費者和零售管道，量身定做健康和休閒產品，優先考慮用戶體驗和便利性。

第四，建構監管情報能力，以預測政策變化並積極與監管機構和標準制定機構互動。最後，透過透明的採購資訊揭露、第三方檢測以及將科學發現轉化為實際利益的消費者教育項目，建立品牌信任。透過整合這些策略支柱，企業可以將自身的技術差異轉化為廣泛的市場地位和永續成長。

透過整合相關人員訪談、技術文獻研究以及監管審查和綜合分析等穩健的混合方法研究途徑，獲得可操作的營運和策略洞察。

本分析的調查方法結合了對行業相關人員的定性訪談、文獻綜述以及對公開監管指南和同行評審文獻的技術審查。主要訪談包括與研發負責人、供應鏈高管、監管專家和商業策略家進行結構化對話，以了解當前營運挑戰和不斷變化的優先事項。這些對話旨在就提取選擇、配方限制和市場推廣權衡等方面獲得可操作的見解。

輔助資料來源包括近期發表的關於大麻素藥理學的同行評審研究、分析實驗室發布的關於檢測和穩定性方法的白皮書，以及有關產品分類和標籤的司法管轄區政策更新。此外，還對提取平台和生產流程進行了技術評估，以評估規模、成本促進因素和雜質控制要求。對於已發表證據有不足之處的情況，我們進行了專家三角驗證，以提供解釋性背景和風險框架。

貫穿始終，該方法優先考慮對假設進行透明記錄，並對新出現的科學訊號進行保守解讀。因此，此綜合分析強調了營運考量、監管管道和策略影響，而非商業性推測，從而確保建議以可操作且可觀察的產業實踐為依據。

結論強調，在不斷變化的環境中，需要科學嚴謹性、營運韌性和因地制宜的商業化策略來抓住機會。

總之，次要大麻素是一個複雜且快速發展的領域，科學發現、監管合規和消費者需求在此交會融合，共同打造差異化的商業性管道。為了使這一領域成熟，企業必須投資於嚴謹的分析能力、穩健的供應鏈以及符合當地法律規範和通路預期的打入市場策略。那些能夠獲得可靠的科學檢驗並展現生產一致性的企業，將更有能力將其技術優勢轉化為持久的品牌價值。

此外，積極與監管機構溝通以及採取多元化的籌資策略對於應對貿易動態和政策不確定性至關重要。將科研機構和商業性夥伴聚集在一起的合作模式可以加速證據生成，同時分散研發風險。最後，清晰的消費者教育和透明的品質保證措施對於建立信任以及促進產品在醫療、健康和休閒等不同應用情境中的廣泛應用至關重要。

隨著次要大麻素生態系統的不斷發展，那些採用綜合方法，將研究的嚴謹性、營運的韌性和市場敏銳性相結合的組織，將最有能力應對複雜性並抓住最具吸引力的機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 酵母生物工程在商業化生產高純度CBG方面取得了快速進展
  • 消費者越來越偏好微劑量THCV產品來抑制食慾和提升能量。
  • 擴大第三方檢測標準，以認證全球供應鏈中微量大麻素的純度
  • 製藥公司與大麻種植者結成策略聯盟，共同開發新型次要大麻素療法
  • 歐盟監管政策的改變簡化了小劑量大麻素藥物的核准程序。
  • 綠色萃取技術的創新旨在減少次要大麻素分離過程對環境的影響
  • 一種吸入式 CBG 輸送系統的出現，該系統經過最佳化，可快速緩解成年消費者的焦慮情緒。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的次要大麻素市場

  • 大麻色烯
  • 大麻酚
  • 大麻酚
  • Delta-8-THC
  • THCV

9. 按應用分類的次要大麻素市場

  • 醫療保健
    • 神經系統疾病
    • 疼痛管理
    • 皮膚病
    • 睡眠障礙
  • 休閒
    • 休閒用途
    • 感官增強
  • 健康
    • 營養補充品
    • 健身恢復
    • 緩解壓力

第10章 按形式分類的次要大麻素市場

  • 飲料
    • 能量飲料
    • 注入水
    • 茶
  • 膠囊
  • 食用
    • 烘焙點心
    • 巧克力
    • 軟糖
  • 油
  • 酊劑
  • 外用藥物
    • 香脂
    • 奶油
    • 洗劑

第11章 按分銷管道分類的次要大麻素市場

  • 藥局
    • 成人藥房
    • 授權零售商
    • 醫療藥房
  • 電子商務
    • 直接面對消費者
    • 市場
  • 藥局
    • 醫院藥房
    • 零售藥房
  • 健康商店

12. 依最終用途產業分類的次要大麻素市場

  • 化妝品
    • 護髮
    • 化妝品
    • 護膚
  • 飲食
    • 飲料
    • 糖果甜點
    • 小吃
  • 營養補充品
    • 機能性食品
    • 補充
  • 個人護理
  • 製藥
    • 非處方藥
    • 處方藥

第13章 依萃取法分類的次要大麻素市場

  • 二氧化碳萃取
    • 亞臨界
    • 超臨界
  • 乙醇萃取
  • 烴類萃取
    • 丁烷
    • 丙烷
  • 機械萃取

第14章 各地區次要大麻素市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按類別分類的次要大麻素市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國次要大麻素市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Folium Biosciences, Inc.
    • Mile High Labs, LLC
    • CV Sciences, Inc.
    • Botanacor Laboratories, Inc.
    • Bluebird Botanicals, LLC
    • Medical Marijuana, Inc.
    • ProVerde Laboratories, Inc.
    • ExtraktLAB, Inc.
    • Isodiol International Inc.
    • Scandinavian Biopharma AB
Product Code: MRR-3A2E844FF091

The Minor Cannabinoids Market is projected to grow by USD 35.86 billion at a CAGR of 8.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.79 billion
Estimated Year [2025] USD 20.39 billion
Forecast Year [2032] USD 35.86 billion
CAGR (%) 8.41%

The minor cannabinoids landscape has emerged from the shadows of mainstream cannabinoids to become a distinct field of scientific inquiry and commercial experimentation. These compounds, present in smaller concentrations in the cannabis plant, are attracting attention for their differentiated pharmacology, unique sensory profiles, and potential avenues for product innovation. As research deepens and extraction and formulation capabilities improve, developers, clinicians, and consumer brands are converging around opportunities to harness minor cannabinoids' nuanced effects.

Recent advances in analytical chemistry and targeted extraction have lowered technical barriers to isolating compounds such as cannabigerol and cannabichromene, while renewed clinical interest is prompting more rigorous investigation into therapeutic mechanisms. At the same time, consumer curiosity for alternatives to dominant cannabinoids is creating blueprints for novel products positioned within wellness, therapeutic, and recreational contexts. Investors and strategic buyers are watching closely as intellectual property, supply chain resilience, and regulatory clarity become decisive competitive factors.

Consequently, organizations are increasingly prioritizing cross-functional strategies that combine scientific validation, compliant commercialization pathways, and differentiated branding. Effective entry now requires synchronized efforts across R&D, regulatory affairs, manufacturing, and go-to-market functions, as the sector shifts from artisanal experimentation to structured product development and institutional investment.

How scientific advances regulatory recalibration and evolving consumer expectations are converging to transform commercialization pathways and strategic priorities across the industry

The industry is undergoing transformative shifts driven by parallel advances in science, regulatory evolution, and consumer demand. On the scientific front, improvements in analytical methods and precision extraction technologies have enabled the characterization and isolation of a broader range of minor cannabinoids than was previously feasible, uncovering distinct receptor interactions and therapeutic hypotheses. As a result, research programs are diversifying beyond the canonical cannabinoids toward molecules that offer subtler or complementary biological effects.

Regulatory landscapes are also shifting, with jurisdictions recalibrating frameworks to address new cannabinoids, adapt labeling and testing requirements, and balance public health concerns with commercial opportunity. These regulatory adjustments are prompting companies to invest in compliance infrastructure and to design products that can withstand greater scrutiny. Concurrently, consumer behavior is evolving: sophisticated wellness seekers and therapeutic users alike are seeking targeted formulations, transparent provenance, and scientifically grounded benefit claims.

In response, incumbents and new entrants are refining go-to-market strategies to emphasize evidence, supply chain traceability, and differentiated product narratives. Investors are increasingly focused on companies that can demonstrate reproducible extraction processes, robust analytical testing, and clear regulatory pathways. Taken together, these dynamics are accelerating the maturation of the sector from exploratory use cases to structured, scalable commercialization models.

Implications of United States tariff adjustments in 2025 on sourcing strategies supply chain resilience and manufacturing partnerships across the minor cannabinoids value chain

Tariff policy adjustments in the United States for 2025 are reshaping cross-border supply chain economics and prompting companies to reassess sourcing and manufacturing footprints. Firms that historically relied on international extraction, formulation, or ingredient supply are now recalculating landed costs, lead times, and inventory strategies in light of tariff shifts that affect the movement of raw botanical material, purified isolates, and finished goods components.

In response to these trade dynamics, many organizations are accelerating near-shoring initiatives, prioritizing domestic extraction capacity, or diversifying supplier networks to mitigate single-source exposure. These adjustments are not solely cost driven; they also reflect the strategic premium placed on supply chain resilience, quality control, and regulatory alignment, especially as domestic authorities increase scrutiny of test results and provenance documentation. Additionally, companies with vertically integrated operations are better positioned to absorb tariff impacts through internal value capture and by leveraging in-house compliance capabilities.

Moreover, the tariff environment is influencing partnership models: contract manufacturers and toll processors are recalibrating service offerings to support multinational clients facing incremental trade costs. Strategic buyers, licensors, and joint venture partners are increasingly evaluating whether collaborative manufacturing investments can neutralize tariff risk while preserving speed to market. Consequently, executives must incorporate tariff scenarios into sourcing decisions and contingency planning to maintain agility amid shifting trade economics.

Comprehensive segmentation framework revealing how product type application form distribution channel end use and extraction method jointly determine strategic product and regulatory choices

Segmentation by product type highlights distinct scientific and commercial considerations across cannabichromene, cannabigerol, cannabinol, delta-8-THC, and THCV, each carrying unique pharmacological profiles that inform formulation strategies and regulatory risk assessments. Likewise, segmentation by application differentiates clinical proof-points and consumer positioning: medical uses span neurological disorders, pain management, skin conditions, and sleep disorders; recreational applications emphasize leisure use and sensory enhancement; wellness focuses on dietary supplements, fitness recovery, and stress relief. These application axes directly influence claims architecture, evidence requirements, and channel suitability.

Form factors shape user experience and operational demands, with beverages, capsules, edibles, oil, tinctures, and topicals each presenting distinct formulation, stability, and dosing challenges. Within beverages, subsegments such as energy drinks, infused water, and teas demand attention to solubility and sensory masking; edibles including baked goods, chocolates, and gummies require robust stability protocols and consistent cannabinoid distribution; topicals represented by balms, creams, and lotions must address skin absorption and preservative systems. Distribution channel segmentation differentiates route-to-consumer approaches, from dispensaries that include adult-use, licensed retailers, and medical outlets, to e-commerce models structured around direct-to-consumer and marketplace strategies, and to pharmacies encompassing hospital and retail pharmacies, each imposing different regulatory and compliance touchpoints.

End use industry segmentation further refines opportunity mapping, with cosmetics spanning haircare, makeup, and skincare; food & beverages covering beverages, confectionery, and snacks; nutraceuticals split between functional foods and supplements; personal care and pharmaceuticals addressing OTC products and prescription drug pathways. Finally, extraction method segmentation-CO2 extraction with subcritical and supercritical modes, ethanol extraction, hydrocarbon extraction with butane and propane variants, and mechanical extraction-determines cost structures, impurity profiles, and scalability. Together, these segmentation lenses provide a multidimensional framework to guide product development, regulatory strategy, and commercial prioritization across the minor cannabinoids ecosystem.

Regional dynamics and regulatory heterogeneity across the Americas Europe Middle East Africa and Asia Pacific that shape tailored commercialization and compliance strategies

Regional dynamics are shaping differentiated pathways for research, regulation, and commercialization across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct investor sentiment, consumer preferences, and policy environments. In the Americas, a mix of mature markets and rapidly evolving state-level regulations encourages innovation in both therapeutic and adult-use spaces, while commercial actors place emphasis on testing infrastructure, supply chain traceability, and retail channel optimization.

Across Europe, Middle East & Africa, regulatory heterogeneity and conservative public health frameworks often necessitate rigorous clinical evidence and clear product definitions; companies targeting these markets are focusing on pharmaceutical pathways, medical product registries, and collaborations with established healthcare providers. In contrast, Asia-Pacific presents a complex mosaic where cultural attitudes, import controls, and varying tolerance for cannabinoid products require carefully tailored go-to-market strategies. Many firms are prioritizing partnerships with local distributors, aligning formulations with regional ingredient standards, and designing educational programs to build consumer trust.

Taken together, these regional insights indicate that successful market approaches will be those that combine local regulatory intelligence with flexible manufacturing and distribution models. Strategic entrants must invest in region-specific compliance, local clinical or safety studies when required, and culturally attuned marketing to accelerate adoption while mitigating regulatory and reputational risk.

Key company capabilities and competitive differentiators including extraction expertise formulation scalability regulatory engagement and distribution reach that determine market leadership

Competitive positioning in the minor cannabinoids sector is defined by capabilities across R&D, extraction and formulation, regulatory affairs, and channel execution. Leading companies distinguish themselves through proprietary extraction know-how, validated analytical methodologies, and demonstrated ability to translate molecular profiles into consistent, reproducible products. Partnerships with academic institutions and contract research organizations are increasingly common as firms seek clinical validation and mechanistic understanding to support credible product claims.

Manufacturing capabilities remain a strategic differentiator: firms that can scale CO2 or ethanol extraction while maintaining rigorous impurity monitoring and batch reproducibility command a tactical advantage. At the same time, companies with flexible formulation platforms capable of addressing beverages, edibles, topicals, and oral dosage forms are better positioned to respond to shifting consumer preferences. Distribution strength, whether through licensed dispensaries, pharmacy channels, or robust direct-to-consumer e-commerce models, also differentiates players by enabling rapid market access and data capture for iterative product refinement.

Intellectual property and regulatory dossiers further separate market leaders from emerging contenders. Organizations that combine defensible process IP with proactive regulatory engagement achieve faster clearance for new products and reduce commercial risk. Collectively, these competencies form the basis for strategic alliances, M&A activity, and licensing transactions as companies seek to round out portfolios and accelerate time to meaningful revenue streams.

Actionable strategic priorities for industry leaders to translate scientific differentiation into resilient supply chains compliant commercialization and trusted consumer propositions

Industry leaders should prioritize an integrated strategy that aligns scientific validation, compliant manufacturing, and consumer education to convert technical potential into commercial results. First, invest in rigorous analytical and preclinical workstreams that establish product reproducibility and clarify mechanism-of-action narratives. These data assets will underpin credible marketing claims and reduce regulatory friction while supporting partnerships with clinical investigators and healthcare stakeholders.

Second, diversify extraction and manufacturing footprints to balance cost efficiency with supply chain resilience. Near-shoring, dual-sourcing, and investments in scalable CO2 or ethanol platforms will help mitigate trade exposure and ensure consistent quality. Third, adopt a channel-specific commercialization approach: design formulations and labeling for dispensaries and medical channels with the evidentiary rigor they demand, while tailoring wellness and recreational products to direct-to-consumer and retail channels that prioritize user experience and convenience.

Fourth, build regulatory intelligence capabilities to anticipate policy shifts and to engage proactively with regulators and standards bodies. Finally, cultivate brand trust through transparent sourcing disclosures, third-party testing, and consumer education programs that translate scientific findings into accessible benefit statements. By integrating these strategic pillars, organizations can convert technical differentiation into defensible market positions and sustainable growth.

Robust mixed methods research approach integrating stakeholder interviews technical literature regulatory review and synthesis to produce actionable operational and strategic insights

Research methodology for this analysis combined primary qualitative interviews with industry stakeholders, secondary literature synthesis, and technical review of publicly available regulatory guidance and peer-reviewed literature. Primary engagements included structured conversations with R&D leaders, supply chain executives, regulatory specialists, and commercial strategists to capture contemporary operational challenges and evolving priorities. These dialogues were designed to surface practical insights into extraction choices, formulation constraints, and go-to-market tradeoffs.

Secondary materials encompassed recent peer-reviewed studies on cannabinoid pharmacology, white papers from analytical laboratories on assay and stability methodologies, and jurisdictional policy updates relevant to product classification and labeling. Additionally, technical evaluation of extraction platforms and manufacturing processes informed assessments of scale, cost drivers, and impurity control requirements. Where gaps in published evidence existed, triangulation with subject-matter experts provided interpretive context and risk framing.

Throughout, the approach prioritized transparent documentation of assumptions and a conservative interpretation of emerging scientific signals. The resulting synthesis emphasizes operational considerations, regulatory pathways, and strategic implications rather than speculative commercial projections, ensuring that recommendations are actionable and grounded in observable industry practice.

Concluding synthesis highlighting the need for scientific rigor operational resilience and regionally adapted commercialization strategies to capture opportunity in the evolving landscape

In conclusion, minor cannabinoids represent a nuanced and rapidly evolving domain where scientific discovery, regulatory adaptation, and consumer demand intersect to create differentiated commercial pathways. The sector's maturation requires companies to invest in rigorous analytical capabilities, resilient supply chains, and tailored go-to-market strategies that align with regional regulatory frameworks and channel expectations. Those who secure credible scientific validation and demonstrate manufacturing consistency will be best positioned to translate technical differentiation into durable brand value.

Moreover, proactive regulatory engagement and diversified sourcing strategies will be essential to manage trade dynamics and policy uncertainty. Collaborative models that pair scientific institutions with commercial partners can accelerate evidence generation while spreading development risk. Finally, clear consumer education and transparent quality assurance practices will be central to building trust and enabling broader adoption across medical, wellness, and recreational use cases.

Organizations that adopt an integrated approach-melding research rigor, operational resilience, and market acuity-will be able to navigate complexity and seize the most compelling opportunities as the minor cannabinoids ecosystem continues to develop.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid advancements in yeast bioengineering to produce high purity CBG at commercial scale
  • 5.2. Growing consumer preference for microdosing THCV products targeting appetite suppression and energy
  • 5.3. Introduction of functional beverage lines fortified with CBN and CBD blends for enhanced sleep support
  • 5.4. Expansion of third-party testing standards to authenticate minor cannabinoid purity in global supply chains
  • 5.5. Strategic alliances between pharmaceutical companies and cannabis cultivators to develop novel minor cannabinoid therapies
  • 5.6. Regulatory updates in the European Union enabling streamlined approval pathways for minor cannabinoid pharmaceuticals
  • 5.7. Innovations in green extraction technologies reducing environmental impact of minor cannabinoid isolation processes
  • 5.8. Emergence of inhalable CBG delivery systems optimized for rapid onset anxiety relief in adult consumers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minor Cannabinoids Market, by Product Type

  • 8.1. Cannabichromene
  • 8.2. Cannabigerol
  • 8.3. Cannabinol
  • 8.4. Delta-8-Thc
  • 8.5. Thcv

9. Minor Cannabinoids Market, by Application

  • 9.1. Medical
    • 9.1.1. Neurological Disorders
    • 9.1.2. Pain Management
    • 9.1.3. Skin Conditions
    • 9.1.4. Sleep Disorders
  • 9.2. Recreational
    • 9.2.1. Leisure Use
    • 9.2.2. Sensory Enhancement
  • 9.3. Wellness
    • 9.3.1. Dietary Supplements
    • 9.3.2. Fitness Recovery
    • 9.3.3. Stress Relief

10. Minor Cannabinoids Market, by Form

  • 10.1. Beverages
    • 10.1.1. Energy Drinks
    • 10.1.2. Infused Water
    • 10.1.3. Teas
  • 10.2. Capsules
  • 10.3. Edibles
    • 10.3.1. Baked Goods
    • 10.3.2. Chocolates
    • 10.3.3. Gummies
  • 10.4. Oil
  • 10.5. Tinctures
  • 10.6. Topicals
    • 10.6.1. Balms
    • 10.6.2. Creams
    • 10.6.3. Lotions

11. Minor Cannabinoids Market, by Distribution Channel

  • 11.1. Dispensaries
    • 11.1.1. Adult-Use Dispensaries
    • 11.1.2. Licensed Retailers
    • 11.1.3. Medical Dispensaries
  • 11.2. E-Commerce
    • 11.2.1. Direct-To-Consumer
    • 11.2.2. Marketplaces
  • 11.3. Pharmacies
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
  • 11.4. Wellness Stores

12. Minor Cannabinoids Market, by End Use Industry

  • 12.1. Cosmetics
    • 12.1.1. Haircare
    • 12.1.2. Makeup
    • 12.1.3. Skincare
  • 12.2. Food & Beverages
    • 12.2.1. Beverages
    • 12.2.2. Confectionery
    • 12.2.3. Snacks
  • 12.3. Nutraceuticals
    • 12.3.1. Functional Foods
    • 12.3.2. Supplements
  • 12.4. Personal Care
  • 12.5. Pharmaceuticals
    • 12.5.1. Otc Products
    • 12.5.2. Prescription Drugs

13. Minor Cannabinoids Market, by Extraction Method

  • 13.1. Co2 Extraction
    • 13.1.1. Subcritical
    • 13.1.2. Supercritical
  • 13.2. Ethanol Extraction
  • 13.3. Hydrocarbon Extraction
    • 13.3.1. Butane
    • 13.3.2. Propane
  • 13.4. Mechanical Extraction

14. Minor Cannabinoids Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Minor Cannabinoids Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Minor Cannabinoids Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Folium Biosciences, Inc.
    • 17.3.2. Mile High Labs, LLC
    • 17.3.3. CV Sciences, Inc.
    • 17.3.4. Botanacor Laboratories, Inc.
    • 17.3.5. Bluebird Botanicals, LLC
    • 17.3.6. Medical Marijuana, Inc.
    • 17.3.7. ProVerde Laboratories, Inc.
    • 17.3.8. ExtraktLAB, Inc.
    • 17.3.9. Isodiol International Inc.
    • 17.3.10. Scandinavian Biopharma AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EXTRACTION METHOD, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EXTRACTION METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MINOR CANNABINOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINOR CANNABINOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MINOR CANNABINOIDS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MINOR CANNABINOIDS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MINOR CANNABINOIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL MINOR CANNABINOIDS MA